GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Race Oncology Ltd (ASX:RAC) » Definitions » Total Assets

Race Oncology (ASX:RAC) Total Assets : A$21.67 Mil (As of Dec. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Race Oncology Total Assets?

Race Oncology's Total Assets for the quarter that ended in Dec. 2024 was A$21.67 Mil.

During the past 12 months, Race Oncology's average Total Assets Growth Rate was -60.70% per year. During the past 3 years, the average Total Assets Growth Rate was -14.80% per year. During the past 5 years, the average Total Assets Growth Rate was -3.70% per year.

During the past 9 years, Race Oncology's highest 3-Year average Total Assets Growth Rate was 6.80%. The lowest was -14.80%. And the median was -0.80%.

Total Assets is connected with ROA %. Race Oncology's annualized ROA % for the quarter that ended in Dec. 2024 was 4.79%. Total Assets is also linked to Revenue through Asset Turnover. Race Oncology's Asset Turnover for the quarter that ended in Dec. 2024 was 0.00.

Race Oncology Total Assets Historical Data

The historical data trend for Race Oncology's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Race Oncology Total Assets Chart

Race Oncology Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Total Assets
Get a 7-Day Free Trial Premium Member Only 5.93 14.25 37.53 26.64 20.23

Race Oncology Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 31.59 26.64 21.07 20.23 21.67

Race Oncology Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Race Oncology's Total Assets for the fiscal year that ended in Jun. 2024 is calculated as

Total Assets=Total Equity (A: Jun. 2024 )+Total Liabilities (A: Jun. 2024 )
=18.312+1.916
=20.23

Race Oncology's Total Assets for the quarter that ended in Dec. 2024 is calculated as

Total Assets=Total Equity (Q: Dec. 2024 )+Total Liabilities (Q: Dec. 2024 )
=20.715+0.957
=21.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Race Oncology  (ASX:RAC) Total Assets Explanation

Total Assets is connected with ROA %.

Race Oncology's annualized ROA % for the quarter that ended in Dec. 2024 is

ROA %=Net Income (Q: Dec. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Dec. 2024 ))/ count )
=1.004/( (20.229+21.672)/ 2 )
=1.004/20.9505
=4.79 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Race Oncology's Asset Turnover for the quarter that ended in Dec. 2024 is

Asset Turnover
=Revenue (Q: Dec. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Dec. 2024 ))/ count )
=0/( (20.229+21.672)/ 2 )
=0/20.9505
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Race Oncology Total Assets Related Terms

Thank you for viewing the detailed overview of Race Oncology's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Race Oncology Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Race Oncology Ltd (ASX:RAC) » Definitions » Total Assets
Comparable Companies
ASX:DXB ASX:IMU ASX:PAR ASX:ACW ASX:AGN ASX:ALA ASX:LTP ASX:EZZ ASX:PIQ ASX:RAD VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
1 Macquarie Place, Level 36, Gateway, Sydney, NSW, AUS, 2000
Website
https://www.raceoncology.com
Race Oncology Ltd is a clinical stage biopharmaceutical company with a mission to be at the heart of cancer care. Its asset, bisantrene, is a small molecule chemotherapeutic. Bisantrene has a clinical history with demonstrated therapeutic benefits in both adult and pediatric patients, a well-characterized safety profile, and compelling clinical data demonstrating an anticancer effect and less cardiotoxicity over certain anthracyclines, such as doxorubicin. It has reformulated bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a clinical focus on anthracycline combinations, where Race can deliver cardioprotection and enhanced anticancer activity in solid tumors.